



U.S. Food and Drug Administration
Protecting and Promoting Public Health

www.fda.gov

Unique Device Identification (UDI) in Administrative Transactions

Thomas P. Gross, MD, MPH
Director, Office of Surveillance and Biometrics
Center for Devices and Radiological Health



National Committee on Vital and Health Statistics
Subcommittee on Standards
June 10, 2014
Washington, D.C.





Strengthening Our National System


Taking the Next Steps





Proposed Specific Actions to Strengthen Device Postmarket Surveillance

- 1) Establish a UDI System and Promote the Incorporation of UDI into Electronic Health Information (EHI)
- 2) Promote the Development of National and International Device Registries for Selected Products
- 3) Modernize Adverse Event Reporting and Analysis
- 4) Develop and Use New Methods for Evidence Generation, Synthesis, and Appraisal





Purpose, Value, Benefits

- UDI provides standard, unambiguous means to document device use in various EHI
- UDI in claims provides a complementary data source
 - Can generate population-based data on device exposures
 - Useful for assessing public health and/or regulatory planning, impact
 - Can generate population-based data on health outcomes of interest (related to specific device exposures)
 - Useful for assessing device benefit/risk in real-world setting
 - Can provide longitudinal profile of patient experience
 - Potentially useful for baseline active surveillance (e.g., implant revision rates)
 - Useful for easier and more accurate linkage across data sources
- UDI in claims may facilitate recall effectiveness



Steps Taken to Implement UDI

- Implemented a fully functional global UDI (GUDID) database
- Advocated for incorporation of UDI into EHRs as part of EHR certification (technical specifications and meaningful use)
- Completed a pilot demonstrating challenges in incorporating UDI into hospital information systems
- Completed Brookings-convened thinktanks to inform UDI “roadmap” on challenges in incorporating UDI into claims, EHRs, and providing patient and provider access
- Participated in WEDI/Pew stakeholder meetings on facilitating capture and transmission of UDI



CDRH Use of Claims Data

- Multi-Payer Claims Database
 - Pilot under auspices of ASPE and CMS
 - CMS and commercial payer data
- SafeRx
 - CMS initiative launched with Part D
 - Medicare and Medicaid data
- Registry Linkage
 - FDA in collaboration with professional societies



Sentinel Initiative and Devices

- Sentinel focused on drugs/biologics
- Expansion of Sentinel to include devices required under FDA Safety and Innovation Act of 2012
- Current records accessible to Sentinel lack manufacturer or brand-specific device identifiers
- **Device Uses**
 - utilization of hip arthroplasty devices by articulating surface
 - safety evaluation of robotically-assisted surgery



Additional Considerations

- Ability to assess real world benefit/risk of devices anticipated to have positive impact on healthcare costs and inefficiencies
- Need to identify specific versions of device to understand public health impact of that version
- Absent UDI, payers are limited in ability to reimburse for specific devices based on value



Conclusions

- UDI in claims provides a complementary data source to strengthen national postmarket surveillance
- UDI is a key data element that can transform claims data and its impact on public health
- FDA recognizes the challenges faced by multiple stakeholders in incorporating UDI into claims
- Question is what is the appropriate path forward to make it happen in pragmatic and cost-effective manner?